{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06196203",
            "orgStudyIdInfo": {
                "id": "AK117-205"
            },
            "organization": {
                "fullName": "Akeso",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",
            "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "a-study-of-in-combination-with-azacitidine-in-patients-with-myelodysplastic-syndromes"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-24",
            "studyFirstSubmitQcDate": "2023-12-24",
            "studyFirstPostDateStruct": {
                "date": "2024-01-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Akeso",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS)."
        },
        "conditionsModule": {
            "conditions": [
                "Higher-risk Myelodysplastic Syndromes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AK117 (dose 1) in combination with azacitidine",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects receive AK117 (dose 1) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously",
                    "interventionNames": [
                        "Drug: AK117",
                        "Drug: Azacitidine"
                    ]
                },
                {
                    "label": "AK117 (dose 2) in combination with azacitidine",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects receive AK117 (dose 2) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously",
                    "interventionNames": [
                        "Drug: AK117",
                        "Drug: Azacitidine"
                    ]
                },
                {
                    "label": "Placebo in combination with azacitidine",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subjects receive placebo intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Azacitidine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AK117",
                    "description": "AK117 IV injection",
                    "armGroupLabels": [
                        "AK117 (dose 1) in combination with azacitidine",
                        "AK117 (dose 2) in combination with azacitidine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo IV injection",
                    "armGroupLabels": [
                        "Placebo in combination with azacitidine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Azacitidine",
                    "description": "Azacitidine SC injection",
                    "armGroupLabels": [
                        "AK117 (dose 1) in combination with azacitidine",
                        "AK117 (dose 2) in combination with azacitidine",
                        "Placebo in combination with azacitidine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Complete remission rate (CRR)",
                    "description": "CRR is defined as the proportion of subjects with complete remission (CR) per International Working Group (IWG) 2023 criteria",
                    "timeFrame": "Up to approximately 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "The proportion of subjects with recorded response per IWG 2023",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Time to response (TTR)",
                    "description": "Time from the randomization to the first recorded response",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Time to CR (TTCR)",
                    "description": "Time from the randomization to the first recorded CR",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Duration of response (DoR)",
                    "description": "Time from the first recorded response until disease relapse or progression or death due to any cause, whichever occurs first",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Duration of CR (DoCR)",
                    "description": "Time from the first recorded CR until disease relapse or progression or death due to any cause, whichever occurs first",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Event-free survival (EFS)",
                    "description": "Time from randomization until transformation to AML or death due to any cause, whichever occurs first",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "The time from randomization until death due to any cause",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of subjects with adverse events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Pharmacokinetic characteristics",
                    "description": "Serum concentrations of AK117 in individual subjects at different time points after AK117 administration",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Anti-drug antibody (ADA)",
                    "description": "Number of subjects with detectable anti-drug antibodies",
                    "timeFrame": "Up to approximately 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old at the time of enrolment.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.\n* Expected life expectancy \u2265 3 months.\n* Newly diagnosed HR-MDS, according to the 2016 World Health Organization (WHO) classification with the presence of \\< 20% blasts in bone marrow or peripheral blood; Overall IPSS-R score \u2265 3.5.\n* Ability to undergo the study-required bone marrow sample collection procedures.\n* Suitable venous access for the study-required blood sampling (i.e., including PK and immunogenicity).\n* Female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the informed consent and a negative urine pregnancy test on the day of first dose prior to dosing.\n* Female patients of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 180 days after the last dose of the study treatment.\n* Unsterilized male patients having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 180 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN).\n* Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRP\u03b1)-targeting agents.\n* Concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n* Patients who previously diagnosed with another malignancy and have any evidence of residual disease.\n* Known allergy to any component of any study drug; known history of severe hypersensitivity to other monoclonal antibodies.\n* Patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study.\n* Patients with current hypertension with systolic blood pressure \u2265 160 mmHg or diastolic blood pressure \u2265 100 mmHg after oral antihypertensive therapy.\n* Patients with known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.\n* Patients who are breastfeeding or plans to breastfeed during the study.\n* Other conditions where the investigator considers the patient inappropriate for enrollment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jie Yang, MD",
                    "role": "CONTACT",
                    "phone": "+86(0760)89873999",
                    "email": "clinicaltrials@akesobio.com"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Ronald Reagan Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Rocky Mountain Cancer Centers",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80012",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Yale Cancer Center",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Mid Florida Hematology and Oncology Center",
                    "status": "RECRUITING",
                    "city": "Orange City",
                    "state": "Florida",
                    "zip": "32763",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.94888,
                        "lon": -81.29867
                    }
                },
                {
                    "facility": "American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda)",
                    "status": "RECRUITING",
                    "city": "Bethesda",
                    "state": "Maryland",
                    "zip": "20817",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.98067,
                        "lon": -77.10026
                    }
                },
                {
                    "facility": "Maryland Oncology-Columbia",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "Maryland",
                    "zip": "21044",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.24038,
                        "lon": -76.83942
                    }
                },
                {
                    "facility": "Washington University School of Medicine in St. Louis",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "UNC Lineberger Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27514",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Gabrail Cancer Center",
                    "status": "RECRUITING",
                    "city": "Canton",
                    "state": "Ohio",
                    "zip": "44718",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.79895,
                        "lon": -81.37845
                    }
                },
                {
                    "facility": "MUSC Hollings Cancer Center",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Institute of hematolongy&blood diseases hospital, chinese academy of medical sciences&peking union medical college",
                    "status": "RECRUITING",
                    "city": "Tianjin",
                    "country": "China",
                    "contacts": [
                        {
                            "name": "Zhijian Xiao",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.14222,
                        "lon": 117.17667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001374",
                    "term": "Azacitidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4673",
                    "name": "Azacitidine",
                    "asFound": "Pilot Study",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}